TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma

The past decade has witnessed the gradual and steady progress of adoptive T cell therapy in treating various types of cancer. In combination with gemcitabine and carboplatin chemotherapy, we previously conducted a clinical trial, NCT00690872, to treat Epstein-Barr virus (EBV)-positive nasopharyngeal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guoping, Mudgal, Poorva, Wang, Liuyang, Shuen, Timothy Wai Ho, Wu, Haiyang, Alexander, Peter B, Wang, Who-Whong, Wan, Ying, Toh, Han Chong, Wang, Xiao-Fan, Li, Qi-Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331028/
https://www.ncbi.nlm.nih.gov/pubmed/34377592
http://dx.doi.org/10.1080/2162402X.2021.1955545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331028/
https://www.ncbi.nlm.nih.gov/pubmed/34377592
http://dx.doi.org/10.1080/2162402X.2021.1955545

Ejemplares similares